OncoMatch/Clinical Trials/JS207

JS207 (JS207) Clinical Trials

JS207 is a recombinant humanized anti-PD-1/VEGF bispecific antibody developed by Junshi Biosciences, designed to simultaneously block the PD-1/PD-L1 axis and inhibit VEGF-driven angiogenesis with VEGF-binding affinity designed to be comparable to bevacizumab. With numerous ongoing Phase 2 studies, JS207 is being evaluated in NSCLC (including neoadjuvant settings for resectable disease), colorectal cancer, triple-negative breast cancer, and hepatocellular carcinoma, both as monotherapy and in combination with chemotherapy, checkpoint antibodies, and ADCs. Junshi filed an IND with FDA clearance for a Phase 2/3 study comparing JS207 to nivolumab for neoadjuvant treatment of resectable AGA-negative NSCLC. Eligibility criteria vary by indication and arm; most NSCLC trials specify actionable genomic alteration (AGA) status — meaning whether a known targetable mutation such as EGFR, ALK, or ROS1 is present — and some specify PD-L1 expression thresholds (perioperative and neoadjuvant trials may not).